Updated:
Karyopharm Therapeutics
Richard Paulson leads Karyopharm, the biotech that turned nuclear export inhibition into a commercial oncology franchise with its XPO1 drug selinexor.
Karyopharm Therapeutics
Karyopharm Therapeutics was founded in 2008 by Dr. Sharon Shacham, who pioneered the science of Selective Inhibitor of Nuclear Export compounds that target XPO1, a protein overexpressed in many cancers. The company went public in 2013 and secured accelerated FDA approval for its lead drug, selinexor (XPOVIO), in 2019 for relapsed/refractory multiple myeloma. The founding science originated from academic research on nuclear transport pathways, and Dr. Shacham served as Chief Scientific Officer through the company's clinical validation and commercialization phases. Karyopharm deploys its capital almost entirely into clinical development and commercialization of its XPO1 inhibitor pipeline. Beyond the flagship multiple myeloma franchise, the company has pursued label expansions into diffuse large B-cell lymphoma and endometrial cancer, the latter representing a newer market. Its development strategy relies on combination regimens with existing standards of care—bortezomib, dexamethasone, and daratumumab in multiple myeloma, and with chemotherapy in other solid and hematologic tumors. The geographic footprint covers the United States through a direct commercial sales force, with ex-U.S. rights partnered to regional pharma companies including Menarini Group in Europe and Antengene in Asia-Pacific. A second-generation asset, eltanexor, was studied for myelodysplastic syndromes, though development has been deprioritized. Karyopharm reported 382 employees at year-end 2024, with operations centered in Newton, Massachusetts. The company commercialized selinexor through its own specialty oncology sales organization and has historically funded operations through a mix of equity offerings and debt, including a royalty-backed financing facility with HealthCare Royalty Partners. A pivotal 2024 leadership transition placed Richard Paulson, formerly of Ipsen, into the CEO role, succeeding long-time CEO Michael Kauffman who had led the company since near inception. In May 2024, the company announced it had met the primary endpoint in its Phase 3 SENTRY trial for myelofibrosis, a key pipeline expansion target that, if successful, would mark its entry into a large myeloproliferative neoplasm market. Karyopharm's structural differentiator is its sole-dependence on a single validated biological mechanism for all pipeline value, making its corporate fate unusually binary among mid-cap biotechs. The company does not diversify across unrelated platforms or therapeutic areas. Its capital allocation is tied to extracting maximum label expansion and survival data from the XPO1 hypothesis, funded through pharmaceutical operating revenue and structured financing rather than multi-asset portfolio theory. Succession in 2024 to a commercial-oriented CEO signals a shift from founder-led R&D to market-penetration leadership.
General information
Firm type
Asset Manager
Year founded
2008
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Newton
Corporate office
Newton, MA, United States
Principals
Richard Paulson
President & Chief Executive Officer
Michael Mano
Senior Vice President, General Counsel & Secretary
Reshma Rangwala
Executive Vice President, Chief Medical Officer
Sector focus
Frequently asked questions
Who founded Karyopharm and what was the core scientific insight?
Dr. Sharon Shacham founded Karyopharm in 2008 based on research into XPO1, a nuclear export protein that removes tumor suppressor proteins from the cell nucleus in many cancers. Her team developed Selective Inhibitors of Nuclear Export (SINE) compounds that trap these suppressors inside the nucleus, restoring the cell's ability to undergo apoptosis. Shacham served as Chief Scientific Officer through the company's formative clinical years and IPO.
What is Karyopharm's revenue base and how is it structured commercially?
Karyopharm generates commercial revenue through direct U.S. sales of XPOVIO (selinexor) to oncology treatment centers for multiple myeloma and select lymphoma indications. The company reported approximately $140-150 million in annual net product revenue across 2023 and 2024. Outside the United States, the firm monetizes selinexor through regional licensing deals with partners like Menarini Group (Europe) and Antengene (China and Asia-Pacific), receiving milestone payments and royalties.
What clinical-stage pipeline indications does Karyopharm pursue beyond multiple myeloma?
The lead expansion indications are endometrial cancer — where a Phase 3 study (SIENDO) evaluated selinexor as maintenance therapy — and myelofibrosis, where the Phase 3 SENTRY trial met its primary endpoint in 2024. The company has also explored selinexor in glioblastoma and liposarcoma. A second-generation XPO1 inhibitor, eltanexor, was previously in development for myelodysplastic syndromes but was not prioritized for further investment.
How does Karyopharm fund its operations given it is not yet consistently profitable?
The company funds the gap between commercial revenue and operating expenses through a mix of equity sales and structured debt. In 2022 and 2023, Karyopharm entered into royalty-backed financing agreements, including with HealthCare Royalty Partners, monetizing a portion of future selinexor royalties for upfront cash. The company also carried convertible senior notes. Management has publicly targeted reaching a self-sustaining, operating-profitable model through revenue growth and pipeline prioritization.
Who runs investment and strategic decisions at Karyopharm?
Strategic and capital-allocation decisions sit with the CEO, currently Richard Paulson as of 2024, and the Board of Directors. Paulson brought commercial and business-development experience from Ipsen. The prior long-serving CEO and co-founder, Dr. Michael Kauffman, remained involved through the transition. Pipeline investment decisions are made by the executive leadership team based on clinical data readouts and market-sizing, rather than through a portfolio committee model.
Does Karyopharm operate any philanthropic or patient-assistance programs?
Yes. Karyopharm maintains a patient support program called KaryForward, which offers financial assistance, insurance navigation, and educational resources to patients prescribed XPOVIO. The program is operated as a standard biopharma patient-services function integrated into the commercial organization, not as an independent philanthropic foundation.
What is Karyopharm's known posture on partnerships versus wholly-owned development?
Karyopharm retains full U.S. commercial rights for selinexor and wholly owns its clinical development programs in its core territories. It partners ex-U.S. commercialization regionally. On the clinical side, Karyopharm has historically self-sponsored its pivotal trials, including combination studies with drugs from other manufacturers — a posture that keeps the selinexor franchise wholly under its operational control rather than co-developed with a large pharma partner.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: